Understanding GLP-1 dosing: Starting low and titrating up All GLP-1 medications (glucagon-like peptide-1 receptor agonists) are initiated at a low dose and their dosage is gradually escalated over time to enhance your bodys tolerability and minimize the risk of side effects, particularly gastrointestinal side effects such as nausea, vomiting, diarrhea, and constipation
Moreover, WES allows for the integration of pharmacogenomic information, particularly exonic variants in genes related to the Absorption, Distribution, Metabolism, and Excretion (ADME) of drugs, which may complement targeted assays traditionally used to calculate pharmacogenetic profiles, with the possibility of expanding the understanding of gene-drug interactions, and indirectly inform potential drugdrug and drug-nutrient interactionswhich will necessarily have to be calculated through other platforms (Whirl-Carrillo et al., 2012)
Action of acetyl-L-carnitine in neurodegeneration and Alzheimers disease
Mutations in these regions alter the GDH antenna-like domain and weaken the binding capacity of GTP binding domains with GTP, thereby compromising the inhibitory effect of GTP on GDH activity
Antioxidant support contributes to maintaining healthy cellular structure and normal physiological function
For a deeper look at how GLP-1 medications may influence nutrient intake, explore our registered dietitians guide to GLP-1 supplementation
